Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 01 2020
20 01 2020
Historique:
pubmed:
4
12
2019
medline:
1
7
2020
entrez:
4
12
2019
Statut:
ppublish
Résumé
DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial design was conducted to investigate the effects of the histone deacetylase inhibitor valproate and all- Two hundred patients (median age, 76 years; range, 61-92 years) ineligible for induction chemotherapy received decitabine (20 mg/m The addition of ATRA resulted in a higher remission rate (21.9% with ATRA The addition of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival extension in these patients with difficult-to-treat disease, without added toxicity.
Identifiants
pubmed: 31794324
doi: 10.1200/JCO.19.01053
doi:
Substances chimiques
Tretinoin
5688UTC01R
Valproic Acid
614OI1Z5WI
Decitabine
776B62CQ27
Banques de données
ClinicalTrials.gov
['NCT00867672']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM